Section 4 of 6
Clinical evidence
225 evidence topics · 31 sources
Study summaries
OptimUM-02
Objective
Study purpose in the ClinicalTrials.gov record
Phase 2a, phase 2b, and phase 3 objectives in the EU trial record
Secondary objectives in the EU trial record
Aim of the primary analysis in the ASCO 2026 abstract
Aim of the subgroup analysis in the ESMO 2026 poster
Location and study date
Study status, dates, and number of sites in the ClinicalTrials.gov record
| Study characteristic | Quoted record |
|---|---|
| Overall status | “Active, not recruiting” |
| Study start (actual) | “2023-10-31” |
| Primary completion (estimated) | “2027-01-15” |
| Study completion (estimated) | “2028-01-15” |
| Sites | “This study has 68 locations” |
| Last update posted | “Last Update Posted 2026-02-17” |
Countries with listed sites in the ClinicalTrials.gov record
| Country | Example of a listed site location |
|---|---|
| United States | “Philadelphia, Pennsylvania, United States, 19107” |
| Australia | “Melbourne, Victoria, Australia, 3000” |
| Belgium | “Brussels, Belgium, 1200” |
| Canada | “Toronto, Ontario, Canada, M5G 2M9” |
| France | “Paris, France, 75005” |
| Germany | “Heidelberg, Baden-Wurttemberg, Germany, 69120” |
| Israel | “Jerusalem, Israel, 91120” |
| Italy | “Milan, Italy, 20133” |
| Netherlands | “Leiden, Netherlands, 2333 ZA” |
| Poland | “Warsaw, Poland, 02-781” |
| Spain | “Madrid, Spain, 28046” |
| Switzerland | “Zurich, Switzerland, 8058” |
| United Kingdom | “Glasgow, United Kingdom, G12 0YN” |
European Union dates in the EU trial record
| Field | Quoted record |
|---|---|
| Start date in the European Union | “2024-10-09” |
| Estimated recruitment start date | “2024-07-01” |
| Estimated global end date | “2027-12-31” |
Enrollment progress in December 2024
Enrollment progress and international sites as of February 2025
Data cutoff of the primary analysis presented at ASCO 2026
Subgroup analysis presented at ESMO 2026
Study design
Multi-stage randomized open-label design in the ClinicalTrials.gov record
Allocation, assignment model, and masking in the ClinicalTrials.gov record
| Design characteristic | Quoted record |
|---|---|
| Allocation | “Randomized” |
| Interventional model | “Sequential Assignment” |
| Masking | “None (Open Label)” |
Randomization ratios and stratification factors in the ASCO 2026 presentation
Randomization of first-line HLA-A2-negative participants in the ASCO 2026 abstract
Random assignment in the phase 2b and phase 3 portions as reported from the ASCO 2026 presentation
Integrated study-in-study design after the FDA Type C meeting, April 2023
Completion of phase 2a dose optimization on an independent data monitoring committee recommendation, December 2024
Crossover from the control arm
No evidence found.
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
| Inclusion criterion | Quoted record |
|---|---|
| Diagnosis | “Histological or cytological confirmed Metastatic Uveal Melanoma” |
| HLA type required | “HLA-A*02:01 negative” |
| Prior therapy | “No prior systemic therapy in the metastatic or advanced setting regional or liver-directed therapy. Ablations or surgical resection of oligometastatic disease, and neoadjuvant or adjuvant therapy is allowed” |
| Measurable disease | “Measurable disease per RECIST 1.1” |
| Ability to take study therapy | “Able to be safely administered and absorb study therapy” |
| Performance status | “ECOG performance status 0 or 1” |
| Life expectancy | “Life expectancy of ≥3 months” |
| Organ function | “Adequate organ function” |
| Ages eligible | “18 Years and older (Adult, Older Adult )” |
Exclusion criteria in the ClinicalTrials.gov record
Prior treatment requirements in the EU trial record
Tissue, measurable disease, and first-line status in the EU trial record
Laboratory thresholds for adequate organ function in the EU trial record
Syncope, cardiac, and concomitant medication exclusions in the EU trial record
Contraindication to comparator options and restricted use of dacarbazine in the EU trial record
Treatment
Darovasertib and crizotinib doses, run-in, and comparator regimens in the ASCO 2026 presentation
| Arm or regimen | Dose shown in the study design figure |
|---|---|
| Phase 2a and phase 2b/3 selected-dose arm, darovasertib | “Darovasertib (300 mg BID)” |
| Phase 2a and phase 2b/3 combination arms, crizotinib | “Crizotinib (200 mg BID)” |
| Phase 2a lower-dose arm, darovasertib | “Darovasertib (200 mg BID)” |
Route and schedule of each intervention in the ClinicalTrials.gov record
| Intervention | Quoted route and schedule |
|---|---|
| IDE196 (darovasertib) and crizotinib | “Dosed orally, twice daily” |
| Pembrolizumab | “IV administration every 3 weeks” |
| Ipilimumab | “IV administration every 3 weeks for 4 Cycles” |
| Nivolumab | “IV administration every 3 Weeks for 4 Cycles, thereafter every 4 Weeks maintenance” |
| Dacarbazine | “IV administration every 3 Weeks” |
Comparator stratum in the investigator's choice arm (ASCO 2026 presentation)
| Investigator's choice treatment at baseline (stratification), n (%) | Investigator's choice arm (N=103) |
|---|---|
| Ipilimumab + nivolumab | “79 ( 76.7)” |
| Pembrolizumab or dacarbazine | “24 ( 23.3)” |
Comparator selection in the investigator's choice arm, ESMO 2026 poster
Comparator received in the control arm as reported from the ASCO 2026 presentation
Comparator composition in the topline release, which differs from the ASCO and ESMO counts
Study outcomes
Rationale for using progression-free survival by blinded independent central review as the primary endpoint
Primary endpoints of each stage in the ClinicalTrials.gov record
Definitions of progression-free survival and overall survival in the EU trial record
Primary and other endpoints in the ASCO 2026 abstract
Median progression-free survival as the accelerated approval endpoint after the FDA Type C meeting, April 2023
Overall survival as the primary endpoint of the phase 3 confirmatory portion in the annual report for 2024
Accelerated approval on a surrogate endpoint as described in the annual report for 2025
Regulatory role of each primary endpoint in the full enrollment release, December 2025
Regulatory role of each primary endpoint in the topline and ASCO 2026 releases
FDA guidance on progression-free survival as a regulatory endpoint
FDA guidance on blinded central review of tumor-based endpoints
FDA guidance on overall survival as an endpoint
FDA draft guidance on a single randomized trial supporting accelerated approval and verifying benefit
Historical progression-free and overall survival in metastatic uveal melanoma cited in the ESMO 2026 poster
Disease control definition and imaging interval as reported from the ASCO 2026 presentation
Secondary efficacy and safety endpoints in the ClinicalTrials.gov record
Definitions of response endpoints in the EU trial record
Patient-reported outcome endpoints in the ClinicalTrials.gov record and the EU trial record
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment of 420 participants in the current ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Enrollment (estimated) | “420” |
Planned enrollment of 420 participants from record version 39, November 2024
| Field | Quoted record |
|---|---|
| Record version viewed | “Viewing V39 (2024-11-05)” |
| Enrollment | “420 [Estimated]” |
Planned enrollment of 380 participants in record version 1, August 2023, superseded in November 2024
| Field | Quoted record |
|---|---|
| Record version viewed | “Viewing V1 (2023-08-03)” |
| Enrollment | “380 [Estimated]” |
Planned phase 2 and phase 3 sample sizes after the FDA Type C meeting, April 2023, superseded in December 2025
Completed enrollment of 435 participants in the full enrollment release, December 2025
Completed enrollment of 437 participants in the annual report for 2025
Statistical design of the phase 2b primary analysis in the ASCO 2026 presentation
Participants analyzed in the ASCO 2026 release
Testing hierarchy and alpha allocation for secondary endpoints and overall survival
No evidence found.
Description of analysis sets
Intent-to-treat efficacy population of the phase 2b portion in the ASCO 2026 presentation
Safety population of 338 and efficacy population of 313 in the ASCO 2026 abstract
Stratified and unstratified subgroup models in the ESMO 2026 poster
Results
Participant disposition
Participants without a post-baseline response assessment, by arm (ASCO 2026 presentation)
| Best overall response category | Darovasertib plus crizotinib (N=210), n (%) | Investigator's choice (N=103), n (%) |
|---|---|---|
| Not reported (no post-baseline assessment), by BICR and by investigator | “12 (5.7)” | “24 (23.3)” |
Median follow-up and median duration of treatment in the ASCO 2026 presentation
Discontinuation of study treatment for adverse events, ASCO 2026 abstract
Baseline characteristics
Demographics, performance status, and LDH stratum (ASCO 2026 presentation)
| Characteristic | Darovasertib plus crizotinib (N=210) | Investigator's choice (N=103) |
|---|---|---|
| Age, mean (range), years | “61.1 (22 - 85)” | “61.5 (29 - 85)” |
| Female, n (%) | “101 (48.1)” | “52 (50.5)” |
| Race, White, n (%) | “177 (84.3)” | “83 (80.6)” |
| Race, non-White, n (%) | “4 (1.9)” | “4 (3.9)” |
| Race, not reported, n (%) | “29 ( 13.8)” | “16 ( 15.5)” |
| ECOG 0, n (%) | “162 (77.1)” | “87 (84.5)” |
| ECOG 1, n (%) | “48 (22.9)” | “16 (15.5)” |
| Stratification LDH at baseline (IRT), ≤ ULN, n (%) | “120 (57.1)” | “62 (60.2)” |
| Stratification LDH at baseline (IRT), > ULN to < 2x ULN, n (%) | “65 (31.0)” | “29 (28.2)” |
| Stratification LDH at baseline (IRT), ≥ 2x ULN, n (%) | “25 (11.9)” | “12 (11.7)” |
Baseline tumor characteristics and metastatic sites (ASCO 2026 presentation)
| Characteristic | Darovasertib plus crizotinib (N=210) | Investigator's choice (N=103) |
|---|---|---|
| Time since first metastatic diagnosis, median (range), years | “0.18 (0.0 – 8.1)” | “0.19 (0.0 – 4.6)” |
| Size of largest metastatic lesion ≤ 3 cm, n (%) | “119 ( 56.7)” | “67 ( 65.0)” |
| Size of largest metastatic lesion 3.1 to 8.0 cm, n (%) | “73 ( 34.8)” | “31 ( 30.1)” |
| Size of largest metastatic lesion ≥ 8.1 cm, n (%) | “18 ( 8.6)” | “5 ( 4.9)” |
| Hepatic disease only, n (%) | “127 ( 60.5)” | “65 ( 63.1)” |
| Extrahepatic disease only, n (%) | “11 ( 5.2)” | “7 ( 6.8)” |
| Hepatic and extrahepatic disease, n (%) | “72 ( 34.3)” | “31 ( 30.1)” |
Comparator stratum and prior oligometastatic surgery (ESMO 2026 poster)
| Characteristic | Darovasertib 300 mg plus crizotinib 200 mg (N=210) | Investigator's choice (N=103) |
|---|---|---|
| Control at baseline, ipilimumab + nivolumab, n (%) | “158 (75.2)” | “79 ( 76.7)” |
| Control at baseline, pembrolizumab or dacarbazine, n (%) | “52 (24.8)” | “24 ( 23.3)” |
| Prior oligometastatic-directed surgery, n (%) | “5 (2.4)” | “6 (5.8)” |
Balance of baseline characteristics as reported from the ASCO 2026 presentation
Efficacy results
Progression-free survival, 313 participants of the phase 2b/3 portion, data cutoff January 23, 2026
| Outcome | By blinded independent central review | By investigator assessment |
|---|---|---|
| Median PFS, darovasertib plus crizotinib, months (95% CI) | “Darova + Criz: 6.9 (5.6, 8.3)” | “Darova + Criz: 6.7 (5.6, 8.2)” |
| Median PFS, control, months (95% CI) | “Control: 3.1 (1.8, 4.2)” | “Control: 2.7 (1.7, 4.1)” |
| Hazard ratio (95% CI) | “HR = 0.42 (0.30, 0.59)” | “HR = 0.36 (0.26, 0.50)” |
Objective response, best overall response, duration of response, and disease control, 210 and 103 participants by arm
| Outcome | BICR, darovasertib plus crizotinib (N=210) | BICR, investigator's choice (N=103) | Investigator, darovasertib plus crizotinib (N=210) | Investigator, investigator's choice (N=103) |
|---|---|---|---|---|
| Complete or partial response, n (%) | “78 (37.1)” | “6 (5.8)” | “83 (39.5)” | “2 (1.9)” |
| Objective response rate, 95% CI | “30.6, 44.1” | “2.2, 12.3” | “32.9, 46.5” | “0.2, 6.8” |
| Objective response, odds ratio (95% CI) | “10.8 (4.4, 26.4)” | Reference | “34.6 (8.1, 146.9)” | Reference |
| Median duration of response, months (95% CI) | “6.8 (5.5, 11.3)” | “NE” | “6.8 (4.8, 9.7)” | “NE” |
| Complete response, partial response, or stable disease for at least 12 weeks, n (%) | “154 (73.3)” | “32 (31.1)” | “156 (74.3)” | “28 (27.2)” |
| Disease control rate, 95% CI | “66.8, 79.2” | “22.3, 40.9” | “67.8, 80.1” | “18.9, 36.8” |
| Disease control, odds ratio (95% CI) | “7.7 (4.3, 13.5)” | Reference | “9.5 (5.3, 17.0)” | Reference |
| Best overall response, n (%) | BICR, darovasertib plus crizotinib (N=210) | BICR, investigator's choice (N=103) | Investigator, darovasertib plus crizotinib (N=210) | Investigator, investigator's choice (N=103) |
|---|---|---|---|---|
| Complete response | “5 (2.4)” | “0” | “0” | “0” |
| Partial response | “73 (34.8)” | “6 (5.8)” | “83 (39.5)” | “2 (1.9)” |
| Stable disease | “107 (51.0)” | “43 (41.7)” | “99 (47.1)” | “39 (37.9)” |
| Progressive disease | “13 (6.2)” | “29 (28.2)” | “15 (7.1)” | “34 (33.0)” |
| Non-evaluable by RECIST | “0” | “1 (1.0)” | “1 (0.5)” | “4 (3.9)” |
Response, disease control, and duration of response, ASCO 2026 abstract
Tumor shrinkage on waterfall plots and subgroup consistency as reported from the ASCO 2026 presentation
Objective response and median progression-free survival by BICR in subgroups, efficacy population of 313 participants (ESMO 2026 poster, stratified analysis)
| Subgroup (n, darovasertib plus crizotinib and control) | ORR by BICR, darovasertib plus crizotinib (%) | ORR by BICR, control (%) | Median PFS by BICR, darovasertib plus crizotinib (months) | Median PFS by BICR, control (months) |
|---|---|---|---|---|
| LDH normal (n=120, 62) | “46.7” | “8.1” | “8.4” | “4.2” |
| LDH above ULN and below 2x ULN (n=65, 29) | “27.7” | “3.4” | “5.7” | “1.8” |
| LDH 2x ULN or higher (n=25, 12) | “16.0” | “0” | “3.1” | “1.7” |
| Hepatic metastases (n=127, 65) | “45.7” | “3.1” | “8.3” | “2.9” |
| Extrahepatic metastases only (n=11, 7) | “27.3” | “0” | “6.7” | “8.3” |
| Hepatic and extrahepatic metastases (n=72, 31) | “23.6” | “12.9” | “4.9” | “2.8” |
| ECOG PS 0 (n=162, 87) | “38.3” | “5.8” | “6.8” | “3.1” |
| ECOG PS 1 (n=48, 16) | “33.3” | “6.3” | “6.9” | “3.1” |
| Largest lesion below 3 cm (n=119, 67) | “42.9” | “6.0” | “8.3” | “4.0” |
| Largest lesion 3 to 8 cm (n=73, 31) | “34.3” | “6.5” | “5.6” | “1.6” |
| Largest lesion 8 cm or larger (n=18, 5) | “11.1” | “0” | “4.2” | “1.7” |
| Control stratum ipilimumab plus nivolumab (n=158, 79) | “37.3” | “5.1” | “6.9” | “3.1” |
| Control stratum pembrolizumab or dacarbazine (n=52, 24) | “36.5” | “8.3” | “5.8” | “2.8” |
Subgroup findings in the ASCO 2026 and ESMO 2026 releases
Overall survival status at the primary analysis
Secondary endpoint wording in the quarterly report for the first quarter of 2026, which differs from the releases and the presentation
Health-related quality of life and patient-reported outcomes
Quality-of-life data not presented at the ASCO 2026 primary analysis
Safety results
Treatment-related adverse events, phase 2a and 2b safety population of 239 and 100 participants (ASCO 2026 presentation)
“Darovasertib 300mg + crizotinib 200 mg (N=239)” (opens the source at this quote in a new tab)
“Investigator’s Choice (control, N=100)” (opens the source at this quote in a new tab)
| Outcome | Darovasertib plus crizotinib (N=239) | Investigator's choice (N=100) |
|---|---|---|
| Any TRAE, n (%) | “235 (98.3)” | “89 (89.0)” |
| Grade 3 or 4 TRAE, n (%) | “97 (40.6)” | “37 (37.0)” |
| Grade 5 TRAE, n (%) | “1 (0.4)” | “1 (1.0)” |
| Treatment-related serious adverse event, n (%) | “22 (9.2)” | “25 (25.0)” |
| TRAE leading to withdrawal, row not naming a drug, n (%) | “2 (0.8)” | “5 (5.0)” |
| TRAE leading to darovasertib withdrawal, n (%) | “6 (2.5)” | Not applicable |
| TRAE leading to crizotinib withdrawal, n (%) | “24 (10.0)” | Not applicable |
| TRAE leading to investigator's choice withdrawal, n (%) | Not applicable | “19 (19.0)” |
| TRAE leading to darovasertib dose reduction, n (%) | “56 (23.4)” | Not applicable |
| TRAE leading to crizotinib dose reduction, n (%) | “63 (26.4)” | Not applicable |
| Most common TRAE of any grade (20% or more), darovasertib plus crizotinib arm | Darovasertib plus crizotinib (N=239), n (%) |
|---|---|
| Any TRAE | “235 ( 98.3)” |
| Diarrhea | “203 ( 84.9)” |
| Nausea | “179 ( 74.9)” |
| Peripheral edema | “160 ( 66.9)” |
| Vomiting | “119 ( 49.8)” |
| Dermatitis acneiform | “100 ( 41.8)” |
| Fatigue | “94 ( 39.3)” |
| Hypotension | “79 ( 33.1)” |
| Hypoalbuminemia, dysgeusia, and dizziness, each | “61 ( 25.5)” |
| Decreased appetite | “57 ( 23.8)” |
| Most common TRAE of any grade (20% or more), investigator's choice arm | Investigator's choice (N=100), n (%) |
|---|---|
| Any TRAE | “88 ( 88.0)” |
| Diarrhea | “29 ( 29.0)” |
| Alanine aminotransferase increased, aspartate aminotransferase increased, fatigue, and nausea, each | “25 ( 25.0)” |
| Pruritus | “24 ( 24.0)” |
| Grade 3 or 4 TRAE (2% or more), darovasertib plus crizotinib arm | Darovasertib plus crizotinib (N=239), n (%) |
|---|---|
| Any grade 3 or 4 adverse event | “97 ( 40.6)” |
| Diarrhea | “24 ( 10.0)” |
| Syncope | “17 ( 7.1)” |
| Hypotension | “9 ( 3.8)” |
| Nausea and peripheral edema, each | “7 ( 2.9)” |
| Anemia | “6 ( 2.5)” |
| Grade 3 or 4 TRAE (2% or more), investigator's choice arm | Investigator's choice (N=100), n (%) |
|---|---|
| Any grade 3 or 4 adverse event | “37 ( 37.0)” |
| Alanine aminotransferase increased and aspartate aminotransferase increased, each | “7 ( 7.0)” |
| Diarrhea | “6 ( 6.0)” |
| Hepatitis | “5 ( 5.0)” |
| Colitis | “4 ( 4.0)” |
| Lipase increased, autoimmune hepatitis, and amylase increased, each | “3 ( 3.0)” |
| Tubulointerstitial nephritis, hypophysitis, and hyperthyroidism, each | “2 ( 2.0)” |
Treatment-emergent adverse events of any cause, ASCO 2026 abstract
Treatment-related serious adverse events of 25.3% in the control arm, ASCO 2026 abstract
Treatment-related serious adverse events of 25.0% in the control arm and grade 3 or 4 events, ASCO 2026 release
Grade 3 or higher adverse events in the topline release
Management of hypotension and syncope as reported from the ASCO 2026 presentation
Study limitations
Summary
OptimUM-02 is open label, with no masking. The primary analysis was reported at a median follow-up of 7.4 months; OS, the phase 3 primary endpoint, was not mature, and no OS estimate has been reported. The efficacy population of 313 participants is the intent-to-treat population of the phase 2b portion, which the topline release describes as enrolled in the phase 2b/3 portion; the safety analyses use different denominators, 338 participants in the ASCO 2026 abstract and 239 and 100 participants from phases 2a and 2b in the presentation. Reported enrollment is 435 participants in the full enrollment release and 437 in the annual report for 2025.
The comparator was investigator's choice: 79 participants (76.7%) received ipilimumab plus nivolumab, 24 (23.3%) pembrolizumab, and none dacarbazine (the topline release gives 78 and 25), and the EU trial record restricts dacarbazine to settings where immunotherapy is deemed likely to cause irreversible serious adverse events. No post-baseline response assessment was available for 24 participants (23.3%) in the control arm and 12 (5.7%) in the combination arm; 17 control participants withdrew consent before treatment. More participants in the combination arm had ECOG performance status 1 (22.9% vs 15.5%) and a largest metastatic lesion of 8.1 cm or more (8.6% vs 4.9%). Subgroups with LDH 2 times the ULN or higher, target lesion 8 cm or larger, or extrahepatic-only metastases had small numbers of participants and 95% confidence intervals that included the null value. Quality of life by the EORTC QLQ-C30 was a stated endpoint, and quality-of-life data were not presented at ASCO 2026. TRAEs led to dose reduction of darovasertib in 23.4% and of crizotinib in 26.4% of participants.
The sources conflict on several figures: the quarterly report for the first quarter of 2026 describes a statistically significant improvement in OS rate, while the presentation and releases describe OS as immature; any-grade TRAEs in the control arm are 89 (89.0%) in the summary table and 88 (88.0%) in the table of common events; treatment-related serious adverse events in the control arm are 25.0% in the presentation and release and 25.3% in the abstract; and one treatment-related fatal adverse event is reported in each arm while the grade 5 hepatic failure in the combination arm is described as considered unrelated by the sponsor.
Small subgroups with wide confidence intervals, ESMO 2026 poster
Discussant comments on immature overall survival, baseline imbalance, dose reductions, and open questions
OptimUM-01
Objective
First-line cohort: safety and efficacy of darovasertib plus crizotinib in the phase 2 expansion
Registry title and purpose of the basket study
HLA-A∗02:01-positive expansion: analysis of participants treated with darovasertib plus crizotinib
First-line and pretreated cohorts: evaluation of the combination
Location and study date
Registry study dates
| Study characteristic | Quoted record |
|---|---|
| Study start (actual) | “2019-06-28” |
| Primary completion (estimated) | “2027-01-29” |
| Study completion (estimated) | “2027-06-15” |
Registry study sites
| Country | Quoted site |
|---|---|
| United States | “UCLA Medical Center” |
| United States | “San Francisco Oncology Associates” |
| United States | “SCRI - Denver” |
| United States | “University of Iowa” |
| United States | “Cancer Hematology Centers Western Michigan” |
| United States | “Columbia University Medical Center - Herbert Irving Pavilion” |
| United States | “Duke University Medical Center” |
| United States | “University of Cincinnati Cancer Center” |
| United States | “The Cleveland Clinic Foundation” |
| United States | “Sidney Kimmel Cancer Center at Thomas Jefferson University” |
| United States | “The Sarah Cannon Research Institute/Tennessee Oncology” |
| United States | “The University of Texas MD Anderson Cancer Center” |
| Australia | “Westmead Hospital” |
| Canada | “Princess Margaret Cancer Centre” |
First-line cohort publication: enrolling centers
First-line cohort: data cutoff of May 28, 2025
HLA-A∗02:01-positive expansion: data extract date of March 23, 2026
First-line and pretreated cohorts: data cutoff of August 22, 2023
Study design
First-line cohort: phase 1/2, multicenter, open-label, dose-escalation and expansion design
Registry design: nonrandomized, open-label, sequential assignment
| Study characteristic | Quoted record |
|---|---|
| Other study ID number | “IDE196-001” |
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Sequential Assignment” |
| Masking | “None (Open Label)” |
Registry: crizotinib combination dose optimization, crizotinib monotherapy cohort, and enrollment status by cohort
Registry: enrolling crizotinib combination expansion cohort of HLA-A∗02:01-positive participants with nested pharmacokinetic substudies
Combination dose escalation: 3 + 3 design followed by expansion
HLA-A∗02:01-positive expansion: study design as described in the poster
Eligibility criteria
Inclusion criteria, including documentation required for treatment-naive HLA-A∗02:01-positive participants
Additional inclusion criteria for the crizotinib combination
Additional exclusion criteria for the crizotinib combination
Registry: exclusion criteria of the pravastatin pharmacokinetic substudy
HLA-A∗02:01-positive expansion: eligibility criteria
First-line and pretreated cohorts: eligibility criteria
Treatment
First-line cohort: dose selection, darovasertib run-in, and continuous 28-day cycles
Registry interventions: oral twice-daily dosing in 28-day cycles
First-line and pretreated cohorts: expansion dose of darovasertib 300 mg and crizotinib 200 mg twice a day
Selection of the combination expansion dose for potential registrational studies
Study outcomes
Rationale for using RECIST v1.1 objective response rate as the primary endpoint
First-line cohort: investigator-assessed RECIST v1.1 response and imaging schedule
First-line cohort: end points, with overall survival as an exploratory end point
First-line cohort: definitions of objective response, disease control, and duration of response
First-line cohort: definitions of progression-free survival, overall survival, and molecular response
Registry primary outcomes
Registry secondary outcomes
FDA guidance: objective response rate as a direct measure of antitumor activity evaluable in a single-arm study
FDA guidance: single-arm studies, accelerated approval, and time-to-event end points
IDE196 monotherapy: FDA End-of-Phase 1 feedback on a single-arm design with response rate as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
First-line cohort: 44 participants enrolled and treated, 41 evaluable for response
Registry: estimated enrollment
| Study characteristic | Quoted record |
|---|---|
| Enrollment (estimated), all cohorts of the basket study | “336” |
Pretreated cohort, data cutoff of November 25, 2021: target enrollment of the combination arm and participants enrolled at the expansion dose
First-line and pretreated cohorts, data cutoff of March 8, 2023: safety population of 68 and per-protocol efficacy population of 63 participants
HLA-A∗02:01-positive expansion: 101 participants treated
Description of analysis sets
First-line cohort: safety population and efficacy-evaluable population
First-line cohort: three participants excluded from the response analysis
First-line cohort: descriptive analysis without formal hypothesis testing
First-line cohort: censoring rules for progression-free survival
HLA-A∗02:01-positive expansion: efficacy-evaluable population and all-enrolled population
Results
Participant disposition
First-line cohort: discontinuations due to treatment-emergent adverse events
HLA-A∗02:01-positive expansion: discontinuations due to adverse events
First-line and pretreated cohorts, data cutoff of August 22, 2023: duration of treatment and participants continuing treatment
Baseline characteristics
First-line cohort: baseline characteristics of 44 participants
| Characteristic | First-line cohort, N = 44 |
|---|---|
| Age, median years (range) | “64.5 (21, 80)” |
| Age less than 65 years, No. (%) | “22 (50.0)” |
| Female, No. (%) | “21 (47.7)” |
| Male, No. (%) | “23 (52.3)” |
| Race White, No. (%) | “41 (93.2%)” |
| Race Asian, No. (%) | “1 (2.3%)” |
| Race other or not reported, No. (%) | “2 (4.5%)” |
| ECOG PS 0, No. (%) | “27 (61.4)” |
| ECOG PS 1, No. (%) | “17 (38.6)” |
| Baseline LDH normal, No. (%) | “29 (65.9)” |
| Baseline LDH above ULN, No. (%) | “14 (31.8)” |
| Baseline LDH more than 2× ULN, No. (%) | “7 (15.9)” |
| Largest metastatic lesion 3.0 cm or less, No. (%) | “24 (54.5)” |
| Largest metastatic lesion 3.1 to 8.0 cm, No. (%) | “15 (34.1)” |
| Largest metastatic lesion 8.1 cm or more, No. (%) | “4 (9.1)” |
| Metastases hepatic only, No. (%) | “23 (52.3)” |
| Metastases extrahepatic only, No. (%) | “2 (4.5)” |
| Metastases hepatic and extrahepatic, No. (%) | “18 (40.9)” |
| HLA-A∗02:01 negative, No. (%) | “30 (68.2)” |
| HLA-A∗02:01 positive, No. (%) | “12 (27.3)” |
| HLA-A∗02:01 unknown, No. (%) | “2 (4.5)” |
First-line cohort: high-risk features and HLA testing at enrollment
First-line cohort: performance status compared by the sponsor with an earlier registrational study
HLA-A∗02:01-positive expansion: baseline characteristics of treatment-naive and overall populations
| Characteristic | Treatment-naive, N = 13 | Overall, N = 101 |
|---|---|---|
| Age, median years (range) | “65.0 (21, 81)” | “66.0 (21, 81)” |
| Female, n (%) | “7 (53.8)” | “44 (43.6)” |
| Race White, n (%) | “13 (100.0)” | “95 (94.1)” |
| ECOG PS 0, n (%) | “6 (46.2)” | “66 (65.3)” |
| ECOG PS 1, n (%) | “7 (53.8)” | “35 (34.7)” |
| Baseline LDH at or below ULN, n (%) | “7 (53.8)” | “36 (35.6)” |
| Baseline LDH above ULN and below 2× ULN, n (%) | “4 (30.8)” | “43 (42.6)” |
| Baseline LDH 2× ULN or higher, n (%) | “2 (15.4)” | “22 (21.8)” |
| Metastases hepatic only, n (%) | “8 (61.5)” | “51 (50.5)” |
| Metastases extrahepatic only, n (%) | “2 (15.4)” | “12 (11.9)” |
| Metastases hepatic and extrahepatic, n (%) | “3 (23.1)” | “38 (37.6)” |
| No prior lines of therapy, n (%) | “13 (100)” | “13 (12.9)” |
| Prior lines of therapy | Overall, N = 101, n (%) |
|---|---|
| One prior line of therapy | “20 (19.8)” |
| Two or more prior lines of therapy | “67 (66.3)” |
| Not recorded, previously treated | “1 (1.0)” |
HLA-A∗02:01-positive expansion: prior systemic therapy, including second-line treatment after tebentafusp
First-line and pretreated cohorts, per-protocol efficacy population: tumor burden and HLA-A∗02:01 status
Efficacy results
First-line cohort, efficacy-evaluable population of 41 participants: response, duration of response, and disease control
| Outcome | First-line cohort, N = 41 |
|---|---|
| Objective response rate, No. (%) | “14 (34.1)” |
| Objective response rate, 95% CI | “20.1 to 50.6” |
| Best overall response CR, No. (%) | “0 (0.0)” |
| Best overall response PR, No. (%) | “14 (34.1)” |
| Best overall response SD, No. (%) | “23 (56.1)” |
| Best overall response PD, No. (%) | “4 (9.8)” |
| Duration of response, median months | “9.0” |
| Duration of response, 95% CI | “3.8 to 12.0” |
| Time to response, median months | “2.0” |
| Disease control rate at 8 weeks, No. (%) | “37 (90.2)” |
| Disease control rate at 8 weeks, 95% CI | “76.9 to 97.3” |
| Disease control rate at 26 weeks, No. (%) | “22 (53.7)” |
| Disease control rate at 26 weeks, 95% CI | “37.4 to 69.3” |
First-line cohort: tumor shrinkage
First-line cohort, safety population: progression-free survival and overall survival at a median follow-up of 25 months
First-line cohort: progression-free survival and overall survival with confidence intervals as stated in the abstract
First-line cohort: confirmed response by HLA-A∗02:01 status
| Outcome | HLA-A∗02:01 positive, n = 10 | HLA-A∗02:01 negative, n = 29 |
|---|---|---|
| Objective response rate, No. (%) | “3 (30.0)” | “9 (31.0)” |
| Objective response rate, 95% CI | “3.7 to 65.2” | “15.3 to 50.8” |
| Best overall response PR, No. (%) | “3 (30.0)” | “9 (31.0)” |
| Best overall response SD, No. (%) | “7 (70.0)” | “16 (55.2)” |
| Best overall response PD, No. (%) | “0 (0.0)” | “4 (13.8)” |
| Disease control rate, No. (%) | “10 (100.0)” | “25 (86.2)” |
| Disease control rate, 95% CI | “NA” | “68.3 to 96.1” |
| Duration of response, median months | “10.15” | “9.03” |
| Duration of response, 95% CI | “3.75 to NE” | “1.94 to 9.03” |
| Time to response, median months | “3.7” | “1.9” |
First-line cohort: response in HLA-A∗02:01-positive participants as stated in the discussion
First-line cohort: response by baseline LDH
| Outcome | LDH at or below ULN, n = 28 | LDH above ULN to 2× ULN, n = 7 | LDH above 2× ULN, n = 6 |
|---|---|---|---|
| Objective response rate, No. (%) | “8 (28.6)” | “2 (28.6)” | “4 (66.7)” |
| Objective response rate, 95% CI | “13.2 to 48.7” | “3.7 to 71.0” | “22.3 to 95.7” |
| Best overall response SD, No. (%) | “17 (60.7)” | “4 (57.1)” | “2 (33.3)” |
| Best overall response PD, No. (%) | “3 (10.7)” | “1 (14.3)” | “0 (0.0)” |
| Disease control rate, No. (%) | “25 (89.3)” | “6 (85.7)” | “6 (100)” |
First-line cohort: response by tumor burden (largest metastatic lesion)
| Outcome | 3 cm or less, n = 23 | Above 3 cm to 8 cm, n = 15 | Above 8 cm, n = 3 |
|---|---|---|---|
| Objective response rate, No. (%) | “9 (39.1)” | “4 (26.7)” | “1 (33.3)” |
| Objective response rate, 95% CI | “19.7 to .61.5” | “7.8 to 55.1” | “0.8 to 90.6” |
| Best overall response SD, No. (%) | “14 (60.9)” | “7 (46.7)” | “2 (66.7)” |
| Best overall response PD, No. (%) | “0 (0.0)” | “4 (26.7)” | “0 (0.0)” |
| Disease control rate, No. (%) | “23 (100.0)” | “11 (73.3)” | “3 (100.0)” |
First-line cohort: molecular response in circulating cell-free DNA
HLA-A∗02:01-positive expansion: response, progression-free survival, and overall survival in treatment-naive and overall populations
| Outcome | Treatment-naive, N = 13 | Overall, N = 101 |
|---|---|---|
| Objective response rate, n/N (%) | “4/11 (36.4)” | “19/86 (22.1)” |
| Objective response rate, 95% CI | “10.9, 69.2” | “13.9, 32.3” |
| Confirmed best overall response CR, n/N (%) | “0/11 (0.0)” | “0/86 ( 0.0)” |
| Confirmed best overall response SD, n/N (%) | “6/11 (54.5)” | “49/86 (57.0)” |
| Confirmed best overall response PD, n/N (%) | “0/11 (0.0)” | “9/86 (10.5)” |
| Confirmed best overall response not evaluable, n/N (%) | “1/11 (9.1)” | “9/86 (10.5)” |
| Disease control rate, n/N (%) | “10/11 (90.9)” | “69/86 (80.2)” |
| Median progression-free survival, 95% CI | “3.6, 19.6” | “3.7, 6.8” |
| Median overall survival, 95% CI | “8.9, NE” | “9.8, 26.3” |
HLA-A∗02:01-positive expansion: second-line participants after tebentafusp
| Outcome | Prior tebentafusp (second line), N = 15 |
|---|---|
| Objective response rate, n/N | “(5/14)” |
| Objective response rate, 95% CI | “12.8-64.9” |
| Disease control rate, % | “85.7%” |
| Disease control rate, n/N | “(12/14)” |
| Median duration of response | “5.6 mos” |
| Median progression-free survival, 95% CI | “3.65-NE” |
| Median overall survival, 95% CI | “9.79-NE” |
HLA-A∗02:01-negative participants of OptimUM-01 as reported for comparison in the HLA-A∗02:01-positive expansion poster
| Outcome | HLA-A∗02:01 negative, treatment-naive, N = 29 | HLA-A∗02:01 negative, overall, N = 61 |
|---|---|---|
| Objective response rate, n/N (%) | “9/29 (31.0)” | “16/61 (26.2)” |
| Objective response rate, 95% CI | “15.3, 50.8” | “15.8, 39.1” |
| Disease control rate, n/N (%) | “25/29 (86.2)” | “53/61 (86.9)” |
| Median progression-free survival, 95% CI | “3.7, 9.2” | “5.0, 7.8” |
| Median overall survival, 95% CI | “12.0, 23.8” | “11.7, 20.7” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
First-line cohort: dose intensity
First-line cohort: treatment-emergent adverse event summary
| Adverse event | All grades, No. (%) | Grade 3 or higher, No. (%) |
|---|---|---|
| Any AE | “44 (100)” | “23 (52.3)” |
| Serious AE | “9 (20.5)” | “8 (18.2)” |
| AE leading to discontinuation | “3 (6.8)” | “1 (2.3)” |
| AEs related to darovasertib leading to reduction | “3 (6.8)” | “0” |
| AEs related to crizotinib leading to reduction | “4 (9.1)” | “1 (2.3)” |
| Diarrhea | “42 (95.5)” | “1 (2.3)” |
| Nausea | “37 (84.1)” | “0” |
| Edema peripheral | “27 (61.4)” | “0” |
| Vomiting | “23 (52.3)” | “0” |
| Dermatitis acneiform | “20 (45.5)” | “0” |
| Hypoalbuminemia | “19 (43.2)” | “1 (2.3)” |
| Fatigue | “18 (40.9)” | “0” |
| Constipation | “13 (29.5)” | “1 (2.3)” |
| Dizziness | “13 (29.5)” | “1 (2.3)” |
| Decreased appetite | “11 (25.0)” | “0” |
| Alanine aminotransferase increased | “9 (20.5)” | “2 (4.5)” |
| Headache | “9 (20.5)” | “0” |
| Aspartate aminotransferase increased | “8 (18.2)” | “1 (2.3)” |
| Cough | “8 (18.2)” | “0” |
| Dyspnea | “8 (18.2)” | “0” |
| Hypophosphatemia | “8 (18.2)” | “0” |
| Hypotension | “8 (18.2)” | “1 (2.3)” |
| Anemia | “7 (15.9)” | “0” |
| Blood alkaline phosphatase increased | “7 (15.9)” | “0” |
| Dysgeusia | “7 (15.9)” | “0” |
| Blood creatinine increased | “6 (13.6)” | “0” |
| COVID-19 | “6 (13.6)” | “0” |
| Generalized edema | “6 (13.6)” | “1 (2.3)” |
| Hypokalemia | “6 (13.6)” | “2 (4.5)” |
| Pruritus | “6 (13.6)” | “0” |
| Rash maculopapular | “6 (13.6)” | “0” |
| Vision blurred | “6 (13.6)” | “2 (4.5)” |
| Blood lactate dehydrogenase increased | “5 (11.4)” | “0” |
| Cancer fatigue | “5 (11.4)” | “0” |
| Face edema | “5 (11.4)” | “0” |
| Gastroesophageal reflux disease | “5 (11.4)” | “0” |
| Iron deficiency anemia | “5 (11.4)” | “3 (6.8)” |
| Periorbital edema | “5 (11.4)” | “0” |
First-line cohort: most common adverse events, grade 3 or higher events, serious adverse events, and deaths
First-line cohort: most common adverse events as stated in the abstract
First-line cohort: treatment-related adverse event summary
| Adverse event | All grades, No. (%) | Grade 3 or higher, No. (%) |
|---|---|---|
| Treatment-related AE | “43 (97.7)” | “12 (27.3)” |
| Treatment-related serious AE | “4 (9.1)” | “3 (6.8)” |
| Treatment-related AE leading to discontinuation | “2 (4.5)” | “1 (2.3)” |
| Diarrhea | “40 (90.9)” | “1 (2.3)” |
| Nausea | “35 (79.5)” | “0” |
| Edema peripheral | “27 (61.4)” | “0” |
| Vomiting | “21 (47.7)” | “0” |
| Dermatitis acneiform | “19 (43.2)” | “0” |
| Hypoalbuminemia | “19 (43.2)” | “1 (2.3)” |
| Fatigue | “17 (38.6)” | “0” |
| Dizziness | “12 (27.3)” | “1 (2.3)” |
| Decreased appetite | “8 (18.2)” | “0” |
| Hypotension | “8 (18.2)” | “1 (2.3)” |
| Constipation | “7 (15.9)” | “0” |
| Aspartate aminotransferase increased | “6 (13.6)” | “0” |
| Dysgeusia | “6 (13.6)” | “0” |
| Rash maculopapular | “6 (13.6)” | “0” |
| Alanine aminotransferase increased | “5 (11.4)” | “1 (2.3)” |
| Anemia | “5 (11.4)” | “0” |
| Blood alkaline phosphatase increased | “5 (11.4)” | “0” |
| Face edema | “5 (11.4)” | “0” |
| Generalized edema | “5 (11.4)” | “0” |
| Hypophosphatemia | “5 (11.4)” | “0” |
| Periorbital edema | “5 (11.4)” | “0” |
| Pruritus | “5 (11.4)” | “0” |
First-line cohort: treatment-emergent serious adverse events
| Serious adverse event | Overall population, N = 44, No. (%) |
|---|---|
| Any serious adverse event | “9 (20.5)” |
| Ascites | “1 (2.3)” |
| Bacteremia | “1 (2.3)” |
| Cancer pain | “1 (2.3)” |
| Cholecystitis | “1 (2.3)” |
| Diarrhea | “1 (2.3)” |
| Fall | “1 (2.3)” |
| Generalized edema | “1 (2.3)” |
| Pulmonary embolism (listed in two rows of the source table) | “1 (2.3)” |
| Pancreatitis acute | “1 (2.3)” |
| Sudden death | “1 (2.3)” |
First-line cohort: hypotension, the most common dose-limiting toxicity of darovasertib monotherapy
First-line cohort: overlapping toxicities of the two agents
HLA-A∗02:01-positive expansion, overall population: treatment-related adverse events
| Adverse event | Overall, N = 101, n (%) |
|---|---|
| Related adverse event | “101 (100)” |
| Related serious adverse event | “12 (11.9)” |
| Related grade 3 or higher adverse event | “38 (37.6)” |
| Related adverse event leading to discontinuation | “9 (8.9)” |
| Related adverse events leading to reduction | “28 (27.7)” |
| Diarrhea | “83 ( 82.2)” |
| Nausea | “77 ( 76.2)” |
| Edema peripheral | “71 ( 70.3)” |
| Vomiting | “58 ( 57.4)” |
| Fatigue | “55 ( 54.5)” |
| Dizziness | “38 ( 37.6)” |
| Dermatitis acneiform | “35 ( 34.7)” |
| Hypotension | “33 ( 32.7)” |
First-line and pretreated cohorts at the expansion dose, safety population: drug-related adverse events
First-line and pretreated cohorts, 68 participants: drug-related adverse events and serious adverse events
Pretreated cohort, 22 participants: drug-related adverse events
Study limitations
Summary
The OptimUM-01 first-line cohort is an open-label, single-arm, nonrandomized expansion of 44 participants, of whom 41 were efficacy-evaluable; the authors describe the data as hypothesis-generating. No formal hypothesis testing was prespecified, and all results were summarized descriptively. Response was assessed by the investigator per RECIST version 1.1. The efficacy-evaluable population required at least one post-baseline tumor assessment, which excluded two participants who discontinued before assessment (one for sudden death) and one ongoing participant; PFS and OS were measured from the first day of treatment in the safety population, and OS is an exploratory end point. The authors state that PFS and OS results are preliminary and that the proportion censored and the medians will change with longer follow-up. Disease control was defined as stable disease lasting at least 8 weeks, where OptimUM-02 required at least 12 weeks. The HLA-A∗02:01 subgroups comprise 29 HLA-A∗02:01-negative and 10 HLA-A∗02:01-positive evaluable participants, and HLA status was unknown for about 5% because testing was not routinely performed at enrollment. Molecular response could be assessed in only the 20 participants with driver mutations reported from tumor tissue. The study reports no quality-of-life or patient-reported outcome results; its end points were safety, ORR, duration of response, disease control rate, PFS, and OS. Comparisons with historical data sets carry, in the authors' words, “the necessary caveats and limitations of cross-study comparisons”.
In the HLA-A∗02:01-positive expansion, response was assessed in an efficacy-evaluable population of participants with at least 3 post-baseline assessments or who discontinued treatment, giving denominators of 11 of 13 treatment-naive and 86 of 101 overall participants. IDEAYA's earlier phase 2 results for 68 participants receiving the combination (data cutoff August 22, 2023) were preliminary and based on investigator review from an unlocked database.
Within the first-line cohort publication, the 95% CIs for median PFS (3.8 to 7.7 months in the results; 5.0 to 8.3 months in the abstract) and median OS (12.5 to 27.1 months; 11.9 to 20.7 months) differ, as do the ORR in HLA-A∗02:01-positive participants (30.0%, 3 of 10, in the subgroup table; 40% in the discussion), the incidence of diarrhea (95.5%; 95.2%), and the incidence of hypotension (18.3%; 18.2%).
First-line cohort: open-label, single-arm design and immature survival data
First-line cohort: cross-study comparisons with historical data
First-line cohort: molecular response limited to participants with known tumor driver mutations
Efficacy by HLA-A2 serotype from a preliminary analysis of an unlocked database as of August 22, 2023
CLXS196X2101
Objective
Primary, secondary, and exploratory objectives of single-agent LXS196
“In this phase I trial, we aimed to evaluate the safety, preliminary efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of LXS196, and to determine the MTD and/or recommended dose for expansion (RDE) of LXS196 as a single agent in patients with MUM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary objectives were to characterise the safety and tolerability and identify the MTD and/or RDE of LXS196 as a single agent in patients with MUM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Secondary objectives included investigation of the preliminary antitumour activity of LXS196 and evaluation of the PK and PD of LXS196.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Exploratory objectives included assessment of mutations in cancer driver genes by transcriptome and targeted DNA sequencing of baseline tumour biopsies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry title and purpose, including a combination part with HDM201
Location and study date
Novartis-sponsored multicenter study initiated on 1 February 2016
Registry protocol number and study dates
| Study characteristic | Quoted record |
|---|---|
| Other study ID number | “CLXS196X2101” |
| Study start (actual) | “2016-02-01” |
| Primary completion (actual) | “2022-01-07” |
| Study completion (actual) | “2022-01-07” |
Registry study sites in six countries
Study design
Dose escalation guided by a Bayesian logistic regression model, followed by expansion at the recommended dose
“Dose escalation was guided by safety, PK data and a two-parameter Bayesian Logistic Regression Model (BLRM) [21] employing escalation with overdose control (EWOC) criteria [22].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Upon determination of the MTD/RDE, the expansion part of the study was opened to further evaluate the safety, tolerability, PK and PD of LXS196 at the RDE in patients with MUM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Once-daily schedule followed by a twice-daily schedule
“Patients were initially treated on a QD schedule (100–1000 mg QD); however, due to toxicities reported at doses ≥500 mg QD, a BID schedule was then tested (200–400 mg BID).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following determination of the MTD in the QD dosing schedule, a BID schedule was introduced to explore whether alternative dosing may lead to better tolerability of LXS196.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry design and status: nonrandomized, open-label, single group; combination part terminated
| Study characteristic | Quoted record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
Eligibility criteria
Adults with biopsy-proven progressive and measurable metastatic disease
“All patients were aged ≥18 years old and had biopsy-proven MUM with progressive and measurable disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1 and requested to provide a tumour biopsy at baseline (pre-treatment) and on treatment at day 15 of cycle 1 (C1D15).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-naive or pretreated disease, with no limit on prior lines
“Patients were either treatment naïve or their disease had progressed (radiologically or clinically) on their most recent therapy. There was no eligibility limit to the number of prior lines of therapy, including PKC inhibitors other than LXS196.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion of cardiac disease, interacting medications, and impaired gastrointestinal function
“Exclusion criteria included impaired cardiac function or clinically significant cardiac diseases, receipt of concomitant medications known to be strong inducers or inhibitors of cytochrome P450 3A4/5 or known for QT prolongation risk, and impaired GI function that could interfere with absorption of LXS196.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry: measurable disease definition, central nervous system metastases, and laboratory exclusions
Treatment
Oral LXS196 once or twice daily in 28-day cycles
“During dose escalation, patients received oral LXS196 either once daily (QD; 100–1000 mg) or twice daily (BID; 200–400 mg) in 28-day cycles until disease progression, intolerable toxicity or withdrawal of consent (Supplementary Fig. 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dosing was omitted on the second day of the first cycle (C1D2) to allow for longer post-dose sampling in order to better characterise PK.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LXS196 was given on an empty stomach, at least 1 h before or 2 h after a meal.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients enroled in the expansion part (n = 12) received LXS196 at the RDE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose adjustments and management of hypotension per protocol
“For patients who did not tolerate their assigned dosing schedule due to a treatment-related AE, dose adjustments were permitted to allow the patient to continue study treatment once the AE had resolved to ≤grade 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using dose-limiting toxicity as the primary endpoint
Dose-limiting toxicity period and evaluability for the dose-escalation model
“The DLT period lasted 28 days after the first dose of LXS196.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A patient was evaluable for the BLRM if the patient took at least 75% of the planned doses during the DLT period or had a DLT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nonclinical findings that anticipated hypotension and gastrointestinal toxicity
“Data from non-clinical single-dose and 4-week repeated dose toxicology studies in dog, suggested that a decrease in systolic blood pressure may be a potential toxicity observed in patients treated with LXS196. The 4-week toxicology study also identified the GI tract as a potential target of LXS196.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety assessments and adverse event grading
“Routine safety assessments, including laboratory assessments, physical examinations, vital signs and electrocardiograms (ECGs), were conducted at regular intervals throughout the study and more frequently as needed following patient assessment by the treating physician.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events (AEs) were assessed continuously according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tumor response by local RECIST v1.1 assessment
“Tumour response was assessed locally by computed tomography (CT) and/or magnetic resonance imaging (MRI) of the chest, abdomen and pelvis, according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 at baseline, on C3D1 and every two cycles thereafter until cycle 11. After 11 cycles of treatment, response was evaluated every three cycles until the end of treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry primary outcomes
Registry secondary outcomes of efficacy and pharmacodynamics
Statistical analysis description
Number of participants (Planned and analyzed)
Single-agent part: 68 participants treated, 56 in dose escalation and 12 in expansion
“A total of 68 patients with MUM were treated with LXS196 in this first-in-human study: 56 in the dose escalation part and 12 in dose expansion (Supplementary Fig. 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients enroled in dose escalation received doses ranging from 100–1000 mg QD (n = 38) and 200–400 mg BID (n = 18) until the RDE was established.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients received LXS196 doses ranging from 100–1000 mg once daily (QD; n = 38) and 200–400 mg twice daily (BID; n = 30).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sample size selected for the dose-escalation model, without a formal calculation
“No hypothesis testing was planned in this study, and therefore, no formal sample size calculation was needed. The sample size was selected to ensure the BLRM had adequate operating characteristics when selecting the MTD/RDE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry: planned enrollment of the single-agent and HDM201 combination parts and actual enrollment
| Study characteristic | Quoted record |
|---|---|
| Enrollment (actual), single-agent and HDM201 combination parts | “107” |
Description of analysis sets
Population evaluable for maximum tolerated dose determination
Response population including participants without post-baseline assessment
“Two patients did not have post-baseline tumour assessments due to clinical disease progression before the first scheduled assessment. Hence, the BOR is unknown per RECIST 1.1, however, they are included in the denominator for ORR and DCR calculations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Estimate [95% CI] for ORR and DCR were obtained using Clopper and Pearson’s method.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descriptive statistics and Kaplan-Meier estimation
“Data are presented using descriptive statistics and visualisations. Continuous variables are described with the mean and range. Categorical variables are described using counts and percentages. PFS is described using the Kaplan–Meier (KM) method.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamic analysis restricted to the once-daily schedule
Results
Participant disposition
Final data cutoff of 7 January 2022: discontinuation in the once-daily schedule
Final data cutoff of 7 January 2022: duration of exposure
“As of the final data cut-off date (7 January 2022), a total of 68 patients had been treated with LXS196 and the median duration of exposure was 3.71 months (range: 1.81–15.28) and 4.6 months (range: 0.33–58.32) for patients in the QD and BID regimens, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single discontinuation due to an adverse event
“The only AE leading to discontinuation of LXS196 was an SAE of grade 3/4 hepatic failure in a patient treated in the BID schedule with known liver metastases and CTCAE grade 2 transaminases at study entry. The event was suspected to be related to underlying disease progression but was not confirmed by radiological assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Baseline characteristics by schedule and at the recommended dose for expansion
Demographics, metastatic sites, and prior therapy
“The median age was 56.0 years, 36 (52.9%) were male, and most (n = 62; 91.2%) had a performance status of 0. The majority of patients (n = 60; 88.2%) had liver metastases, 27 of whom (14 in the BID schedule and 13 in the QD schedule) had only liver metastases and no other sites of disease at study entry.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other reported metastatic sites with an incidence of at least 10% included lung (n = 18, 26.5%), bone (n = 13, 19.1%), lymph node (n = 8, 11.8%) and skin (n = 7, 10.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 59 patients (86.8%) had received prior systemic therapy; the majority having received either one (n = 37, 54.4%) or two prior regimens (n = 14, 20.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The majority of patients (n = 31, 45.6%) had PD as the best overall response (BOR) to their last prior therapy and in these patients, the median time from initiation to discontinuation of last prior therapy was 63 days (range: 14–515).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No patients had received prior tebentafusp.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
GNAQ, GNA11, and BAP1 mutations in baseline tumor biopsies
“Mutations in the GNAQ and GNA11 genes are tabulated (Supplementary Table 5A); of the 48 patients assessed, 28 were mutant in GNA11 (of which 22 had allele Q209L and 6 had R183C), 16 were mutant in GNAQ (of which 13 had allele Q209P, two Q209L, and one R183Q), and 4 were not called mutant in either gene as the allele fraction was below the limit of detection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“BAP1 mutations resulting in a protein coding change were detected in 44% (21/48) of patients (Supplementary Table 5B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Best overall response and progression-free survival by schedule and at the recommended dose for expansion
All participants: response, duration of response, and duration of stable disease
“Clinical activity was observed in 6/66 (9.1%) evaluable patients achieving response (CR/PR), with a median duration of response of 10.15 months (range: 2.99–41.95); 45/66 had stable disease (SD) per RECIST v1.1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median duration of response for all patients with a RECIST response (n = 6) was 10 months (2.99–41.95) and median duration of SD (n = 45) was 5.32 months (2.07–30.23).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Twice-daily schedule and the recommended dose for expansion of 300 mg twice daily: response
“The ORR in the BID schedule was 13.3% (95% CI: 3.8–30.7) and the disease control rate (DCR) was 73.3% (95% CI: 54.1–87.7) (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 18 evaluable patients treated at the RDE of 300 mg BID, 2 (11.1%) had a BOR of PR and 12 (66.7%) had SD (including 3 patients with >30% tumour reduction/unconfirmed PR).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR at the RDE was 11.1% (95% CI: 1.4–34.7) and the DCR was 77.8% (95% CI: 52.4–93.6) (Fig. 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progression-free survival in all participants, the twice-daily schedule, and at the recommended dose for expansion
“No patients were censored and 100% of PFS events were reported as of the data cut-off date. Of the 68 events, 66 had disease progression and 2 patients had died. The estimated median PFS was 3.6 months (95% CI: 3.5–5.4) and the estimated PFS rate at 6 months by the KM method was 29.4% (95% CI: 19.1–40.4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the BID schedule, the estimated median PFS was 4.1 months (95% CI: 3.5–7.2) and the estimated PFS rate at 6 months by the KM method was 33.3% (95% CI: 17.5–50).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the RDE of 300 mg BID, the estimated median PFS was 3.7 months (95% CI: 2.1–5.4) and the estimated PFS rate at 6 months by the KM method was 27.8% (95% CI: 10.1–48.9) (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparison by the authors with the first-generation PKC inhibitor AEB071
“Regarding efficacy, across all doses tested the ORR was 8.8% with LXS196 versus 3% with AEB071, and 67% of patients had SD as their best response with LXS196 versus 50% with AEB071 (median duration of SD: 5.32 versus 3.75 months, respectively). The estimated median PFS was similar at 3.6 months (95% CI: 3.5–5.4) with LXS196 versus 3.5 months (95% CI: 2.5–3.6) with AEB071.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complete response at month 31 reported by the sponsor
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Dose-limiting toxicities and declaration of the maximum tolerated doses and recommended dose for expansion
“First cycle dose-limiting toxicities (DLTs) were observed in 7/38 (18.4%) QD and 2/17 (11.8%) BID patients. Hypotension was the most common DLT, occurring at doses ≥500 mg/day, and manageable with LXS196 interruption and dose reduction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MTDs were declared at 500 mg QD and 400 mg BID, based on the BLRM and EWOC principles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Following the BLRM recommendation guided by EWOC and review of all available safety and PK data, the RDE was declared at 300 mg BID (Supplementary Fig. 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 55 patients evaluable for MTD/RDE determination, DLTs were observed in nine (16.4%) patients (seven patients treated in the QD schedule and two patients in the BID schedule) (Table 2A). The most common DLT was hypotension (n = 6; 10.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other DLTs included nausea and vomiting, neutropenia and generalised oedema (one patient each; 1.8%). GI-related DLTs resolved with temporary interruption of study drug and treatment with anti-emetics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hypotension as a dose-limiting toxicity: timing, presentation, and resolution
“In the QD schedule, hypotension leading to drug interruption and subsequent dose reduction occurred in five patients treated at doses ≥500 mg (two grade 3 events at 500 mg QD, one grade 4 event at 800 mg QD, one grade 4 and one grade 2 event at 1000 mg QD). These events most commonly occurred within 1 to 4 h after the first or second dose and were sometimes accompanied by a transient loss of consciousness with preceding dizziness and sweating.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most events resolved within minutes, some within 4 h, with an infusion of intravenous fluids and 2 patients experienced recurrence of hypotension with 1 patient requiring further LXS196 dose reduction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One DLT of grade 3 hypotension was reported in a patient treated at the highest BID dose tested (400 mg BID).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events suspected to be related to LXS196 by schedule and at the recommended dose for expansion
Grade 3 or higher serious adverse events regardless of relationship, by schedule
| Preferred term | All QD, n = 38 | 300 mg BID (RDE), n = 18 | All BID, n = 30 | All patients, N = 68 |
|---|---|---|---|---|
| Participants with at least 1 serious adverse event, n (%) | “7 (18.4)”View highlighted excerpt for this quote | “5 (27.8)”View highlighted excerpt for this quote | “7 (23.3)”View highlighted excerpt for this quote | “14 (20.6)”View highlighted excerpt for this quote |
| Hypotension, n (%) | “5 (13.2)”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote | “1 (3.3)”View highlighted excerpt for this quote | “6 (8.8)”View highlighted excerpt for this quote |
| Pneumonia, n (%) | “2 (5.3)”View highlighted excerpt for this quote | “1 (5.6)”View highlighted excerpt for this quote | “1 (3.3)”View highlighted excerpt for this quote | “3 (4.4)”View highlighted excerpt for this quote |
Adverse events regardless of relationship, serious adverse events, and tolerability of the two schedules
“The majority of patients (n = 66; 97.1%) experienced an AE regardless of study drug relationship during the study; 29 (42.6%) of these patients experienced AEs of grade 3/4 (Supplementary Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequent AEs with LXS196 (all grades, all doses, both schedules) were nausea (n = 48; 70.6%), diarrhoea (n = 37; 54.4%), vomiting (n = 26; 38.2%), fatigue (n = 19; 27.9%), increased alanine aminotransferase (ALT, n = 18; 26.5%), constipation (n = 17; 25%), asthenia (n = 15; 22.1%) and hypotension (n = 15; 22.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequent AEs of grade ≥3, regardless of study drug relationship, were hypotension (n = 6; 8.8%), increased aspartate aminotransferase (AST, n = 5; 7.4%) and increased ALT (n = 4; 5.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Serious AEs (SAEs) were observed in 14 (20.6%) patients, and all were grade 3/4; the most frequent were hypotension (n = 6; 8.8%) and pneumonia (n = 3; 4.4%) (Table 2C). BID appeared to be better tolerated than QD dosing, with fewer treatment-related grade 3/4 AEs and treatment-related SAEs. Grade 3/4 hypotension was more common in the QD versus the BID groups (13.2% versus 3.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Interruptions and dose reductions as described by the authors
Study limitations
Summary
CLXS196X2101 is a nonrandomized, open-label, single-group phase 1 study of LXS196 (darovasertib) as a single agent, without crizotinib. No hypothesis testing was planned and no formal sample size calculation was made; data are presented descriptively. Of the 68 participants, 59 (86.8%) had received prior systemic therapy, and none had received prior tebentafusp. Participants were treated across once-daily doses of 100 to 1000 mg (n = 38) and twice-daily doses of 200 to 400 mg (n = 30), and 18 were evaluable at the recommended dose for expansion of 300 mg twice daily. Tumour response was assessed locally per RECIST v1.1. The ORR denominator differs between the text (6 of 66 evaluable participants, 9.1%) and the results table, which includes 2 participants without post-baseline assessment in a denominator of 68; the 95% CI of the 6-month PFS rate in all participants is 19.1 to 40.4 in the text and 19.1 to 29.2 in the table. Pharmacodynamic analysis was not performed on tumour samples from the twice-daily schedule, the authors note that the C1D15 biopsy timepoint might be too late to observe transient changes, and the sequencing panel did not include CYSLTR2 and PLCB4. The combination part with HDM201 was terminated early for business reasons. No quality-of-life or patient-reported outcome results were reported; the registry outcomes cover dose-limiting toxicities, adverse events, dose modifications, ORR, PFS, and pharmacodynamics.
Exploratory phase 1 design without formal statistical testing
Timing of on-treatment biopsies for pharmacodynamic assessment
“There are several possible explanations for the lack of correlation between reductions in pMARKCS/pPKCd and clinical activity. One possibility is that the PKC signalling pathway is highly sensitive to LXS196 exposure, and a C1D15 timepoint might be too late to observe transient changes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote